LIANG Jingqiao,JI Chengyu,LI Bo.Experience of XU Xin in Treating Polycystic Ovary Syndrome with Insulin Resistance Based on "Boost Kidney to Dispel the Turbid" Method[J].Journal of Traditional Chinese Medicine,2025,66(02):123-127.
LIANG Jingqiao,JI Chengyu,LI Bo.Experience of XU Xin in Treating Polycystic Ovary Syndrome with Insulin Resistance Based on "Boost Kidney to Dispel the Turbid" Method[J].Journal of Traditional Chinese Medicine,2025,66(02):123-127.DOI: 10.13288/j.11-2166/r.2025.02.004.
To summarize the clinical experience and characteristics of Professor XU Xin in syndrome differentiation and treatment of polycystic ovary syndrome with insulin resistance (PCOS-IR). XU Xin believes that the etiological factors of PCOS-IR is
qi
deficiency of the spleen and kidney, and the key disease mechanism is dysfunction in transportation and transformation of spleen and kidney, causing phlegm dampness and turbid heat accumulated in
yangming
, then evolving into the lower
jiao
, mixed with blood stasis, finally obstructing
the
chong
(冲) and
ren
(任) mai and uterus. So in clinic, the method of boosting the kidney and fortifying the spleen was used through out the whole treatment commonly using modified
Shoutai Pill
(寿胎丸) and
Sijunzi Decoction
(四君子汤). The main therapeutic method for treating PCOS-IR refers to clearing and draining dampness heat in
yangming
, invigorating blood and regulating period, with self-prescribed
Yishen Quzhuo Formula
(益肾祛浊方), as a reference for the treatment of this disease.
ZHAO H , ZHANG J , CHENG X , et al . Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment [J]. J Ovarian Res , 2023 , 16 ( 1 ): 9 .
CHEN T , YU Y , JIA F , et al . The relationship between polycystic ovary syndrome and insulin resistance from 1983 to 2022: a bibliometric analysis [J]. Front Public Health , 2022 , 10 : 960965 . doi: 10.3389/fpubh. 2022. 960965 http://dx.doi.org/10.3389/fpubh.2022.960965 .
ZHOU L , NI Z , YU J , et al . Correlation between fecal metabolomics and gut microbiota in obesity and polycystic ovary syndrome [J]. Front Endocrinol(Lausanne) , 2020 , 11 : 628 . doi: 10.3389/fendo.2020.00628 http://dx.doi.org/10.3389/fendo.2020.00628 .